checkAd
    Startseite > Aktien > OptiNose > Nachrichten
    OptiNose Aktie
    0,7700
     
    EUR
    -3,75 %
    -0,0300 EUR
    Letzter Kurs 30.04.24 Tradegate
    0,8200
     
    EUR
    4.880 STK
    Geldkurs 08:41:47
    0,8700
     
    EUR
    4.572 STK
    Briefkurs 08:41:47
    ISIN: US68404V1008 · WKN: A2H5PR · SYM: 0OP · USA

    Neueste Nachrichten

    Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
    25.04.24 · globenewswire · OptiNose
    Optinose to Present at the Needham Virtual Healthcare Conference
    04.04.24 · globenewswire · OptiNose
    XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
    15.03.24 · globenewswire · OptiNose
    Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
    07.03.24 · globenewswire · OptiNose
    Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
    29.02.24 · globenewswire · OptiNose
    Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
    18.01.24 · globenewswire · OptiNose
    Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference
    22.11.23 · globenewswire · OptiNose
    Optinose Reports Third Quarter 2023 Financial Results and Operational Updates
    09.11.23 · globenewswire · OptiNose
    Optinose Announces Reporting Date for Third Quarter 2023 Financial Results
    27.10.23 · globenewswire · OptiNose
    Optinose to Present at the 2023 Cantor Global Healthcare Conference
    22.09.23 · globenewswire · OptiNose
    Optinose Reports Second Quarter 2023 Financial Results and Operational Updates
    10.08.23 · globenewswire · OptiNose
    Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million
    27.07.23 · globenewswire · OptiNose